Professional

Infectious Diseases

Bacteria and Antibacterial Drugs

Lefamulin

v48471726

Additional Content

Also of Interest

Drug Name

The link you have selected will take you to a third-party website. We do not control or have responsibility for the content of any third-party site.

Leave this Site? 

Facebook

Google+

Key Chapters Consumer

Key Topics it this Section

Language Fallback

Original title:

Generic Drug Names A - Z

LinkedIn

The following topic from the Merck Manual has been sent to you: 
%0D%0A
%0D%0A
{title} 
%0D%0A
%0D%0A
{link} 

Mail

Drug Information

Odnoklassniki

Find information on medical topics, symptoms, drugs, procedures, news and more, written for the health care professional.

Search results for:

Information that is clear and easy to understand on thousands of medical disorders and symptoms

Learn about $SectionName symptoms, diagnosis and treatment in the Merck Manual. HCP and Vet versions too!

Learn about $TopicName symptoms, diagnosis and treatment in the Merck Manual. HCP and Vet versions too!

MerckManuals.com

The trusted provider of medical information since 1899

MERCK MANUAL - Professional Version

IN THIS TOPIC

Topic Resources

TwitterTitle

Was This Page Helpful?

Share to Wechat

Weibo

WERTH BRIAN

<span id="v48471734" class="anchor" ></span><div class="para" > <p >Oral bioavailability is about 25%, and consequently the oral dose is 4 times higher (600 mg every 12 hours) than the IV dose (150 mg every 12 hours). <span class='resolvedDrug' tabindex='0' role='link' productId='5162'>Lefamulin</span> has minimal renal clearance and does not require dose adjustment in patients with kidney disease.</p></div>

Pharmacokinetics

<span id="v48471737" class="anchor" ></span><div class="para" > <p ><span class='resolvedDrug' tabindex='0' role='link' productId='5162'>Lefamulin</span> is indicated for the treatment of community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms:</p></div>

Indications

<span id="v48471754" class="anchor" ></span><div class="para" > <p >Use of <span class='resolvedDrug' tabindex='0' role='link' productId='5162'>lefamulin</span> with CYP3A4 substrates that prolong the QT interval, such as <span class='resolvedDrug' tabindex='0' role='link' productId='587'>tacrolimus</span>, <span class='resolvedDrug' tabindex='0' role='link' productId='705'>dofetilide</span>, and <span class='resolvedDrug' tabindex='0' role='link' productId='798'>quetiapine</span>, is contraindicated.</p></div>

Contraindications

<span id="v48471757" class="anchor" ></span><div class="para" > <p >Animal reproduction studies with <span class='resolvedDrug' tabindex='0' role='link' productId='5162'>lefamulin</span> show some risk, and no adequate, well-controlled studies have been done in pregnant women. Alternatives to <span class='resolvedDrug' tabindex='0' role='link' productId='5162'>lefamulin</span> should be considered in pregnant women until better safety data are available. Females with reproductive potential should use contraception while on therapy and for 2 days after the last dose. </p></div>

Use in Pregnancy and Breastfeeding

<span id="v48471761" class="anchor" ></span><div class="para" > <p ><span class='resolvedDrug' tabindex='0' role='link' productId='5162'>Lefamulin</span> may cause QT prolongation especially if combined with other drugs that prolong the QT interval. </p></div>